RudaCure Inc. fue seleccionada para the Ministry of SMEs and Startups' 2021 Big3 Commercialization Support Project, which will apoyo the comercialización not only of the currently ongoing RCI001, but also of tratamiento del dolor RCI002, atopic dermatitis tratamiento RCI003, anti-metastatic cancer tratamiento RCI004, and age-related macular degeneration tratamiento RCI005.
Along with the previously seleccionada Ministry of Science and ICT Bio iCORE proyecto, la empresa recibió high scores from evaluators across various fields for its nacional e internacional comercialización activities.
En particular, for this Big3 Commercialization Project, la empresa fue reconocida por its ability to secure core tecnología desarrollo through excellent technical personnel and investigación facilities, as well as the management team's capability in tecnología desarrollo and clinical advancement. Como resultado, la empresa recibirá KRW 150 million in financiamiento through the end of este año.
La empresa planea devote all efforts to increasing the value of the drugs currently under desarrollo by accelerating nacional e internacional business activities through various gobierno apoyo programas.